Maternal use of bupropion and risk for congenital heart defects.
OBJECTIVE
We sought to determine if maternal bupropion treatment in early pregnancy is associated with congenital heart defects in the infant.


METHODS
We conducted a retrospective case-control study of birth defects risk factors. Data on 6853 infants with major heart defects were compared with 5869 control infants born in 1997-2004. Bupropion exposure was defined as any reported use between 1 month before and 3 months after conception.


RESULTS
Mothers of infants with left outflow tract heart defects were more likely to have reported taking bupropion than mothers of control infants (adjusted odds ratio, 2.6; 95% confidence interval, 1.2-5.7; P = .01).


CONCLUSIONS
We identified a positive association between early pregnancy bupropion use and left outflow tract heart defects; however, the magnitude of the observed increased risk was small. Nevertheless, further studies are needed to confirm these results.
Alwan
Sura
S
Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Reefhuis
Jennita
J
Botto
Lorenzo D
LD
Rasmussen
Sonja A
SA
Correa
Adolfo
A
Friedman
Jan M
JM
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D016642:Bupropion / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D006330:Heart Defects, Congenital / Q000139:chemically induced*; D006801:Humans; D007231:Infant, Newborn; D007407:Interviews as Topic; D018811:Maternal Exposure / Q000009:adverse effects*; D011247:Pregnancy; D012189:Retrospective Studies
D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion